Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

计划入组 40 人 · 首次发布于 2023 年 3 月 7 日

Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1

计划入组 22 人 · 首次发布于 2025 年 7 月 17 日

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

计划入组 87 人 · 首次发布于 2021 年 5 月 27 日

Sonnet BioTherapeutics Expands SON-1010 Trial After Promising Response Rate in Platinum-Resistant Ovarian Cancer

Sonnet BioTherapeutics Advances SON-1010 Combination Trial for Sarcoma Treatment

GEMMABio Doses First Patient in Phase 1/2 Trial of Next-Generation Gene Therapy GB221 for Spinal Muscular Atrophy Type 1